Catherine H Lee, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 740 Reena Ave, Suite 101, Fort Atkinson, WI 53538 Phone: 920-563-7366 |
Daniel R.b. Fary, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 512 Wilcox St, Fort Atkinson, WI 53538 Phone: 920-563-7366 Fax: 920-563-9061 |
News Archive
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the phase 2b ASPIRE study for TMC435 in treatment experienced hepatitis C patients in a late-breaker session at the 46th Annual meeting of the European Association for the Study of the Liver, Berlin, Germany.
A clinical trial designed to test existing drugs in the treatment of a rare blood cancer has been launched at the Universities of Birmingham and Warwick.
In the health care world, there's not a whole lot that insurers, doctors and union workers all agree on. But a new coalition of powerful Capitol players from all three groups is hoping to reverse recent budget cuts, pushed by Gov. Jerry Brown, to those who provide care to the poorest Californians.
Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite approach, which involves increasing the concentration of "good" HDL cholesterol using nicotinic acid, has proven unpopular among patients up to now. The reason for this is that treatment with nicotinic acid has an unpleasant but harmless side-effect: the drug makes patients turn quite red in the face. Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered the mechanism behind this effect, which is known as flushing. This will enable the development of flush inhibitors and thereby the more effective prevention of cardiovascular diseases.
› Verified 4 days ago